- 24 h
- letzte 200 News
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| 07.04. | China's NMPA authorises Santen's glaucoma treatment application | ||
| 07.04. | Obesity drugs won't be covered by Medicare under 2026 CMS policy | ||
| 07.04. | EC approves AstraZeneca's Imfinzi combo for NSCLC | ||
| 07.04. | ABL Bio and GSK link on neurodegenerative conditions | ||
| 04.04. | Uveitis market expected to reach $1.5bn across 7MM by 2033 | ||
| 04.04. | Daiichi and AstraZeneca's Enhertu gains EC approval for breast cancers | ||
| 04.04. | 'Fear and uncertainty' linger over FDA's future in wake of Trump admin's layoffs | ||
| 04.04. | Streeting promises UK pharma quick action on VPAG frustration | ||
| 04.04. | NBE Therapeutics opens ADC research facility in Switzerland | ||
| 04.04. | Digital cognitive assessments and blood-based biomarkers in Alzheimer's research | ||
| 04.04. | FDA awards ODD status to Sanofi's rilzabrutinib for two rare conditions | ||
| 03.04. | Neurona raises $102m to advance cell therapy for drug-resistant epilepsy | ||
| 03.04. | IO360 Summit: Improving CAR-T cell therapy manufacture and accessibility | ||
| 03.04. | AD/PD 2025: DHTs can detect disease progression in patients with early Parkinson's | ||
| 03.04. | ABPI calls on UK Government to resolve "VPAG crisis" | ||
| 03.04. | Atsena closes $150m in Series C round to progress gene therapy | ||
| 03.04. | IO360 summit: CAR-T cell therapy applications beyond blood cancer | ||
| 03.04. | Pharma industry dodges tariff blow but still braces for disruption | ||
| 03.04. | Weight loss implants to increase compliance and cut admin burden for patients | ||
| 03.04. | FDA grants accelerated approval to Novartis' Vanrafia for IgAN | ||
| 03.04. | The role of thin-layer chromatography (TLC) and high-performance liquid chromatography (HPLC) in modern pharmaceutical and herbal drug analysis | ||
| 03.04. | Astellas Pharma and JFCR partner for oncology research | ||
| 02.04. | UK life sciences venture capital funding lags behind | ||
| 02.04. | US uncertainty weighs on IPO market while UK innovation could benefit | ||
| 02.04. | ACC 2025: GLP-1RAs may reduce incidence of AF/flutter and stroke in diabetic patients |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
